PLB1003

PLB1003 is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), developed by Beijing Purunao Biotechnology (also referred to as Beijing Pearl Biotechnology). It is classified as a second-generation ALK tyrosine kinase inhibitor (TKI) designed to overcome resistance mutations in ALK-positive cancers, particularly non-small cell lung cancer (NSCLC). Preclinical data suggest that PLB1003 has high potency and selectivity for ALK, with potential clinical benefit in patients who have developed resistance to first-generation ALK inhibitors such as crizotinib. The drug acts by blocking abnormal ALK-mediated signaling pathways, leading to inhibition of tumor growth. Phase I clinical trials are ongoing in China for patients with advanced or metastatic ALK-positive NSCLC[1][2][4][5][6].